1. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products CHMP/437/04 Rev 1. 2015. Available at:
https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf
. Accessed 29 July 2019.
2. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for Industry. 2015. Available at:
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
. Accessed 29 July 2019.
3. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues. EMA/CHMP/BMWP/403543/2010. 2012. Available at:
https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf
. Accessed 29 July 2019.
4. De Mora F. Biosimilar: what it is not. Br J Clin Pharmacol. 2015;80:949–56.
5. Prasad V. Non-inferiority trials in medicine: practice changing or a self-fulfilling prophecy? J Gen Intern Med. 2018;33:3–5.